Trends in utilization and complications of catheter ablation for atrial fibrillation in Medicare beneficiaries
- 8 June 2009
- journal article
- research article
- Published by Elsevier in Heart Rhythm
- Vol. 6 (9) , 1267-1273
- https://doi.org/10.1016/j.hrthm.2009.06.009
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Catheter Ablation Versus Antiarrhythmic Drugs for Atrial FibrillationCirculation, 2008
- Long‐Term Clinical Efficacy and Risk of Catheter Ablation for Atrial Fibrillation in the ElderlyJournal of Cardiovascular Electrophysiology, 2008
- Complications of Catheter Ablation for Atrial Fibrillation: Incidence and PredictorsJournal of Cardiovascular Electrophysiology, 2008
- A Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Paroxysmal Atrial FibrillationJournal of the American College of Cardiology, 2006
- Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future PrevalenceCirculation, 2006
- Electrophysiological Findings During Ablation of Persistent Atrial Fibrillation With Electroanatomic Mapping and Double Lasso Catheter TechniqueCirculation, 2005
- Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study)†European Heart Journal, 2005
- Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial FibrillationCirculation, 2005
- Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: Results from the REPLACE-2 trialJournal of the American College of Cardiology, 2004
- Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary interventionResults from the REPLACE-2 trialJournal of the American College of Cardiology, 2004